TransMedics Group, Inc. (NASDAQ:TMDX) Stock Position Lessened by Royce & Associates LP

Royce & Associates LP reduced its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 1.3% during the third quarter, Holdings Channel.com reports. The firm owned 297,198 shares of the company’s stock after selling 4,000 shares during the period. Royce & Associates LP’s holdings in TransMedics Group were worth $46,660,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $47,000. USA Financial Formulas bought a new stake in TransMedics Group during the third quarter worth approximately $55,000. J.Safra Asset Management Corp lifted its position in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC lifted its position in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TMDX shares. Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Needham & Company LLC lowered their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. JPMorgan Chase & Co. dropped their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Finally, Robert W. Baird reduced their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group has a consensus rating of “Buy” and an average target price of $144.80.

TransMedics Group Trading Down 4.7 %

NASDAQ TMDX opened at $88.36 on Friday. The firm’s 50 day moving average price is $127.92 and its two-hundred day moving average price is $139.56. The stock has a market cap of $2.97 billion, a price-to-earnings ratio of 94.00 and a beta of 2.08. TransMedics Group, Inc. has a twelve month low of $63.85 and a twelve month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) earnings per share. Equities analysts anticipate that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock worth $5,230,528 in the last 90 days. Company insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.